Immune Responses to Plasma-Derived Versus Recombinant FVIII Products

The most severe side effect of hemophilia treatment is the inhibitor development occurring in 30% of patients, during the earliest stages of treatment with factor (F)VIII concentrates. These catastrophic immune responses rapidly inactivate the infused FVIII, rendering the treatment ineffective. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Peyvandi, Flora, Miri, Syna, Garagiola, Isabella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862552/
https://www.ncbi.nlm.nih.gov/pubmed/33552050
http://dx.doi.org/10.3389/fimmu.2020.591878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862552/
https://www.ncbi.nlm.nih.gov/pubmed/33552050
http://dx.doi.org/10.3389/fimmu.2020.591878

Ejemplares similares